S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   423.84 (-0.47%)
AAPL   167.09 (-0.54%)
MSFT   404.86 (-1.69%)
META   502.20 (+1.62%)
GOOGL   156.29 (+0.53%)
AMZN   179.43 (-1.02%)
TSLA   150.55 (-3.15%)
NVDA   847.87 (+0.89%)
AMD   154.93 (+0.59%)
NIO   4.02 (+2.81%)
BABA   68.92 (+0.15%)
T   16.28 (+0.99%)
F   12.02 (-0.17%)
MU   112.43 (-3.35%)
GE   153.80 (-1.20%)
CGC   7.92 (+22.03%)
DIS   112.82 (-0.11%)
AMC   2.96 (-0.67%)
PFE   25.38 (-0.16%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   423.84 (-0.47%)
AAPL   167.09 (-0.54%)
MSFT   404.86 (-1.69%)
META   502.20 (+1.62%)
GOOGL   156.29 (+0.53%)
AMZN   179.43 (-1.02%)
TSLA   150.55 (-3.15%)
NVDA   847.87 (+0.89%)
AMD   154.93 (+0.59%)
NIO   4.02 (+2.81%)
BABA   68.92 (+0.15%)
T   16.28 (+0.99%)
F   12.02 (-0.17%)
MU   112.43 (-3.35%)
GE   153.80 (-1.20%)
CGC   7.92 (+22.03%)
DIS   112.82 (-0.11%)
AMC   2.96 (-0.67%)
PFE   25.38 (-0.16%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   423.84 (-0.47%)
AAPL   167.09 (-0.54%)
MSFT   404.86 (-1.69%)
META   502.20 (+1.62%)
GOOGL   156.29 (+0.53%)
AMZN   179.43 (-1.02%)
TSLA   150.55 (-3.15%)
NVDA   847.87 (+0.89%)
AMD   154.93 (+0.59%)
NIO   4.02 (+2.81%)
BABA   68.92 (+0.15%)
T   16.28 (+0.99%)
F   12.02 (-0.17%)
MU   112.43 (-3.35%)
GE   153.80 (-1.20%)
CGC   7.92 (+22.03%)
DIS   112.82 (-0.11%)
AMC   2.96 (-0.67%)
PFE   25.38 (-0.16%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   423.84 (-0.47%)
AAPL   167.09 (-0.54%)
MSFT   404.86 (-1.69%)
META   502.20 (+1.62%)
GOOGL   156.29 (+0.53%)
AMZN   179.43 (-1.02%)
TSLA   150.55 (-3.15%)
NVDA   847.87 (+0.89%)
AMD   154.93 (+0.59%)
NIO   4.02 (+2.81%)
BABA   68.92 (+0.15%)
T   16.28 (+0.99%)
F   12.02 (-0.17%)
MU   112.43 (-3.35%)
GE   153.80 (-1.20%)
CGC   7.92 (+22.03%)
DIS   112.82 (-0.11%)
AMC   2.96 (-0.67%)
PFE   25.38 (-0.16%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
Free Trial
OTCMKTS:ATRX

Adhera Therapeutics (ATRX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free ATRX Stock Alerts
$0.0070
0.00 (0.00%)
(As of 04/17/2024 ET)
Compare
Today's Range
$0.0061
▼
$0.0090
50-Day Range
$0.0070
▼
$0.0168
52-Week Range
$0.01
▼
$0.60
Volume
62,421 shs
Average Volume
116,572 shs
Market Capitalization
$77,560.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsSEC FilingsShort Interest
ATRX stock logo

About Adhera Therapeutics Stock (OTCMKTS:ATRX)

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

ATRX Stock Price History

ATRX Stock News Headlines

January 30, 2024 | investing.com
Adhera Therapeutics Inc (ATRX)
August 24, 2023 | seekingalpha.com
ATRX Adhera Therapeutics, Inc.
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
May 22, 2023 | seekingalpha.com
Intensity Therapeutics upsizes proposed IPO to $15M from $8M
February 27, 2023 | finance.yahoo.com
Adhera Therapeutics, Inc. (ATRX)
January 25, 2023 | finance.yahoo.com
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
January 18, 2023 | seekingalpha.com
CGTX Cognition Therapeutics, Inc.
December 5, 2022 | seekingalpha.com
Adhera Therapeutics files for Nasdaq uplisting, $35M offering
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
October 9, 2022 | benzinga.com
Adhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, Predictions
September 21, 2022 | benzinga.com
Adhera Therapeutics Announces CEO, Senior...
September 19, 2022 | finance.yahoo.com
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
September 19, 2022 | seekingalpha.com
Adhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplist
July 19, 2022 | finance.yahoo.com
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin
May 19, 2022 | seekingalpha.com
Adhera Therapeutics appoints new Chairman of the Board, focuses on uplist to Nasdaq
May 19, 2022 | finance.yahoo.com
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
January 20, 2022 | finance.yahoo.com
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
November 22, 2021 | finance.yahoo.com
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
November 8, 2021 | finance.yahoo.com
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors
October 20, 2021 | apnews.com
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary ...
October 20, 2021 | finance.yahoo.com
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications
October 16, 2021 | apnews.com
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s ...
October 15, 2021 | finance.yahoo.com
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease
October 4, 2021 | finance.yahoo.com
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
September 15, 2021 | insidermonkey.com
5 Penny Stocks with Upcoming Growth Catalysts
September 13, 2021 | apnews.com
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease ...
September 13, 2021 | finance.yahoo.com
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs
See More Headlines
Receive ATRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ATRX
CUSIP
N/A
CIK
737207
Web
adherathera.com
Phone
919-518-3748
Fax
206-830-9424
Employees
2
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,110,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-5,805.73%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($7.02) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
11,080,000
Free Float
7,955,000
Market Cap
$77,560.00
Optionable
Not Optionable
Beta
-0.15
10 Best Stocks to Own in 2024 Cover
10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Andrew Albert Kucharchuk M.B.A. (Age 43)
    Vice Chairman, COO, Acting CFO & Chief Business Officer
    Comp: $285k

Key Competitors

View All Competitors

ATRX Stock Analysis - Frequently Asked Questions

How have ATRX shares performed in 2024?

Adhera Therapeutics' stock was trading at $0.03 at the start of the year. Since then, ATRX shares have decreased by 76.7% and is now trading at $0.0070.
View the best growth stocks for 2024 here.

Are investors shorting Adhera Therapeutics?

Adhera Therapeutics saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 100 shares, a decrease of 95.0% from the February 29th total of 2,000 shares. Based on an average daily volume of 220,800 shares, the days-to-cover ratio is currently 0.0 days.
View Adhera Therapeutics' Short Interest.

When did Adhera Therapeutics' stock split?

Adhera Therapeutics shares reverse split on the morning of Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Adhera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

How do I buy shares of Adhera Therapeutics?

Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ATRX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
The Next Nvidia?
InvestorPlace
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends